Research progress of extracellular vesicles in PMOS: molecular mechanisms, diagnostic value, and therapeutic strategies
- 1Gynecology Department, Shenzhen Traditional Chinese Medicine Hospital
- 2Department of Obstetrics and Gynecology, Key Laboratory and Unit of Infertility in Chinese Medicine, First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine
Abstract
Extracellular vesicles (EVs) carry proteins, lipids and nucleic acids that can influence ovarian and systemic metabolic function. This narrative review examines their molecular mechanisms, biomarker potential and experimental therapeutic applications in polyendocrine metabolic ovarian syndrome (PMOS), previously termed polycystic ovary syndrome. Follicular fluid EV cargo varies with disease phenotype and adiposity, but these associations have not established clinically validated diagnostic tests. Follicular fluid collection also requires an invasive procedure and should not be described as a non-invasive screening approach. Experimental studies indicate that selected mesenchymal stromal cell-derived EV preparations can modulate granulosa cell survival, mitochondrial quality control and endocrine function. Adipose stromal cell- and brown adipose tissue-derived preparations additionally affect metabolic pathways, while engineered small EVs can improve delivery of a PI3K agonist in mice. Disease-associated follicular fluid EVs may impair oocyte maturation or promote abnormal granulosa cell proliferation; their effects depend on source, cargo and recipient context. We distinguish PMOS-specific evidence from chemotherapy-related ovarian injury and premature ovarian insufficiency, summarize treatment models, administration and endpoints, and evaluate reporting in selected studies against MISEV2023 recommendations. The evidence remains predominantly preclinical. Incomplete EV characterization, heterogeneous doses and models, limited biodistribution data and uncertain long-term reproductive safety prevent direct extrapolation to patient care.
Related
- The Role of Neutrophil Extracellular Traps (NETosis) in Systemic Lupus Erythematosus: Molecular Mechanisms, Pathogenic Roles, Diagnostic Biomarkers, and Emerging Therapeutic Strategies
- Extracellular Vesicles in Molecular Crosstalk and Disease Pathogenesis: A Comprehensive Review on Mechanisms and Therapeutic Prospects
- Migrasomes in kidney diseases: emerging molecular mechanisms, diagnostic value, and therapeutic prospects.
- Targeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies.
- Molecular Mechanisms of the Gut-Liver-Placenta Axis in Intrahepatic Cholestasis of Pregnancy: Microbiota-Associated Pathogenesis and Next-Generation Therapeutic Strategies.
BibTeX
@article{qi2026research,
title = {{Research progress of extracellular vesicles in PMOS: molecular mechanisms, diagnostic value, and therapeutic strategies}},
author = {Lijing Qi and Yue Jiang and Yanhua Han and Cong Feng and Liyan Jia and Yuehui Zhang},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1976561},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1976561/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Research progress of extracellular vesicles in PMOS: molecular mechanisms, diagnostic value, and therapeutic strategies
AU - Lijing Qi
AU - Yue Jiang
AU - Yanhua Han
AU - Cong Feng
AU - Liyan Jia
AU - Yuehui Zhang
PY - 2026
DA - 2026/10/20
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1976561
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1976561/full
AB - Extracellular vesicles (EVs) carry proteins, lipids and nucleic acids that can influence ovarian and systemic metabolic function. This narrative review examines their molecular mechanisms, biomarker potential and experimental therapeutic applications in polyendocrine metabolic ovarian syndrome (PMOS), previously termed polycystic ovary syndrome. Follicular fluid EV cargo varies with disease phenotype and adiposity, but these associations have not established clinically validated diagnostic tests. Follicular fluid collection also requires an invasive procedure and should not be described as a non-invasive screening approach. Experimental studies indicate that selected mesenchymal stromal cell-derived EV preparations can modulate granulosa cell survival, mitochondrial quality control and endocrine function. Adipose stromal cell- and brown adipose tissue-derived preparations additionally affect metabolic pathways, while engineered small EVs can improve delivery of a PI3K agonist in mice. Disease-associated follicular fluid EVs may impair oocyte maturation or promote abnormal granulosa cell proliferation; their effects depend on source, cargo and recipient context. We distinguish PMOS-specific evidence from chemotherapy-related ovarian injury and premature ovarian insufficiency, summarize treatment models, administration and endpoints, and evaluate reporting in selected studies against MISEV2023 recommendations. The evidence remains predominantly preclinical. Incomplete EV characterization, heterogeneous doses and models, limited biodistribution data and uncertain long-term reproductive safety prevent direct extrapolation to patient care.
SN - 1664-2392
ER -